Epstein-Barr Virus Vaccine

from Wikipedia, the free encyclopedia

An Epstein-Barr virus vaccine (synonymous EBV vaccine ) is a vaccine against the Epstein-Barr virus . Since EBV is one of the oncoviruses , EBV vaccines are a form of cancer vaccine .

properties

There is still no approved EBV vaccine. Experimental vaccines using as the antigen the EBV protein gp350 / 220 or to CD4 - epitopes -rich C -terminal region of the EBV protein EBNA1 as a fusion protein with LMP2 (engl. English latent membrane protein 2 , membrane protein of the virus latency period ") in full-length , expressed in a modified vaccinia Ankara virus as a viral vector ( MVA-EL ).

Since EBV is a latent virus, combinations of proteins from the lytic and lysogenic cycle are being investigated in order to generate an immune response against both stages of the virus. The immunodominant B-cell - epitopes are the proteins GP350 , VCA , MA , EA (D) , EA (R) and EBNA1 . These are potentially suitable for generating a humoral immune response .

literature

Individual evidence

  1. ↑ WHO | Viral Cancers . Retrieved January 15, 2009.
  2. ↑ a b J. I. Cohen: Epstein-Barr virus vaccines. In: Clinical & translational immunology. Volume 4, number 1, January 2015, p. E32, doi : 10.1038 / cti.2014.27 , PMID 25671130 , PMC 4318489 (free full text).
  3. ↑ Taylor, GS, Haigh, TA, Gudgeon, NH: Dual stimulation of Epstein-Barr Virus (EBV) -specific CD4 + - and CD8 + -T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma . In: J. Virol. . 78, No. 2, January 2004, pp. 768-78. doi : 10.1128 / JVI.78.2.768-778.2004 . PMID 14694109 . PMC 368843 (free full text).
  4. ↑ GS Taylor, H. Jia, K. Harrington, LW Lee, J. Turner, K. Ladell, DA Price, M. Tanday, J. Matthews, C. Roberts, C. Edwards, L. McGuigan, A. Hartley, S. Wilson, EP Hui, AT Chan, AB Rickinson, NM Steven: A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. In: Clinical Cancer Research . Volume 20, number 19, October 2014, pp. 5009-5022, doi : 10.1158 / 1078-0432.CCR-14-1122-T , PMID 25124688 , PMC 4340506 (free full text).
  5. ^ EP Hui, GS Taylor, H. Jia, BB Ma, SL Chan, R. Ho, WL Wong, S. Wilson, BF Johnson, C. Edwards, DD Stocken, AB Rickinson, NM Steven, AT Chan: Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. In: Cancer Research . Volume 73, Number 6, March 2013, pp. 1676–1688, doi : 10.1158 / 0008-5472.CAN-12-2448 , PMID 23348421 .
  6. ↑ Lockey, TD, Zhan, X., Surman, S., Sample, CE, Hurwitz, JL: Epstein-Barr virus vaccine development: a lytic and latent protein cocktail . In: Front. Biosci. . 13, No. 13, 2008, pp. 5916-27. doi : 10.2741 / 3126 . PMID 18508632 .
  7. ↑ JM Middeldorp: Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. In: Current topics in microbiology and immunology. Volume 391, 2015, pp. 289-323, doi : 10.1007 / 978-3-319-22834-1_10 , PMID 26428379 .